Abstract
In the panorama of HIV protease inhibitors (HIV PIs), many efforts have been devoted to the development of new compounds with reduced peptidic nature in order to improve pharmacokinetics and pharmacodynamics features. The introduction of cyclic scaffolds in the design of new chemical entities reduces flexibility and affords more rigid inhibitors. Specifically, common dipeptide isosteres are replaced by a central cyclic scaffold designed to address the key interactions with catalytic aspartic acids and residues belonging to the flap region of the active site. The current interest in cyclic chemotypes addressing key interactions of HIV protease is motivated by the different nature of interactions formed with the enzyme, although maintaining key structural resemblance to a peptide substrate, hopefully giving rise to novel HIV-1 PIs displaying an improved profile towards multidrug resistant strains. This approach has been demonstrated for Tipranavir, which is a potent FDA approved HIV-1 PI representing the most famous example of heterocyclic aspartic protease inhibitors.
Keywords: Amino acid, peptidomimetic, small molecule, enzyme inhibition, infectious disease.
Current Medicinal Chemistry
Title:Heterocyclic HIV-Protease Inhibitors
Volume: 20 Issue: 30
Author(s): C. Calugi, A. Guarna and A. Trabocchi
Affiliation:
- Department of Chemistry “Ugo Schiff”, University of Florence, via della Lastruccia 13, I-50019 Sesto Fiorentino, Florence, Italy.,Italy
Keywords: Amino acid, peptidomimetic, small molecule, enzyme inhibition, infectious disease.
Abstract: In the panorama of HIV protease inhibitors (HIV PIs), many efforts have been devoted to the development of new compounds with reduced peptidic nature in order to improve pharmacokinetics and pharmacodynamics features. The introduction of cyclic scaffolds in the design of new chemical entities reduces flexibility and affords more rigid inhibitors. Specifically, common dipeptide isosteres are replaced by a central cyclic scaffold designed to address the key interactions with catalytic aspartic acids and residues belonging to the flap region of the active site. The current interest in cyclic chemotypes addressing key interactions of HIV protease is motivated by the different nature of interactions formed with the enzyme, although maintaining key structural resemblance to a peptide substrate, hopefully giving rise to novel HIV-1 PIs displaying an improved profile towards multidrug resistant strains. This approach has been demonstrated for Tipranavir, which is a potent FDA approved HIV-1 PI representing the most famous example of heterocyclic aspartic protease inhibitors.
Export Options
About this article
Cite this article as:
Calugi C., Guarna A. and Trabocchi A., Heterocyclic HIV-Protease Inhibitors, Current Medicinal Chemistry 2013; 20(30) . https://dx.doi.org/10.2174/09298673113209990135
DOI https://dx.doi.org/10.2174/09298673113209990135 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |

- Author Guidelines
- Editorial Policies
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Allegations from Whistleblowers
- Publishing Ethics and Rectitude
- Increase Visibility Of Your Article
- Archiving Policies
- Reviewer Guidelines
- Guest Editor Guidelines
- Board Recruitment Workflow
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Announcements
- Forthcoming Thematic Issues
Related Articles
-
Meet Our Editorial Board Member
Current Neuropharmacology Structure-Activity Relationships of Flavonoids
Current Organic Chemistry Hair Regeneration Therapy: Application of Adipose-Derived Stem Cells
Current Stem Cell Research & Therapy Alzheimer’s Disease, Astrocytes and Kynurenines
Current Alzheimer Research Growth Restriction: Etiology, Maternal and Neonatal Outcome. A Review
Current Women`s Health Reviews 2-Aminoimidazole, Glycociamidine and 2-Thiohydantoin-Marine Alkaloids as Molecular Inspirations for the Development of Lead Structures
Current Drug Targets Hyaluronan/Hyaladherins - a Promising Axis for Targeted Drug Delivery in Cancer
Current Drug Delivery 3,5-Bis[4-(diethoxymethyl)benzylidene]-1-methyl-piperidin-4-one, a Novel Curcumin Analogue, Inhibits Cellular and Humoral Immune Responses in Male Balb/c Mice
Current Pharmaceutical Biotechnology Is there a Possible Single Mediator in Modulating Neuroendocrine–thymus Interaction in Ageing?
Current Aging Science Systemic Lupus Erythematosus: Old and New Susceptibility Genes versus Clinical Manifestations
Current Genomics Molecular and Cellular Mechanism of Cutaneous Injuries Due to Exposure to Sulfur Mustard
Letters in Drug Design & Discovery Treatment with Paracetamol is not Associated with Increased Airway Sensitivity and Risk of Asthma in Rats
Current Drug Safety Antiprotozoal Agents: An Overview
Anti-Infective Agents in Medicinal Chemistry Targeting NS5B RNA-Dependent RNA Polymerase for Anti-HCV Chemotherapy
Current Drug Targets - Infectious Disorders Challenges and Opportunities from Basic Cancer Biology for Nanomedicine for Targeted Drug Delivery
Current Cancer Drug Targets Cholinergic Receptors as Target for Cancer Therapy in a Systems Medicine Perspective
Current Molecular Medicine Lactoferrin and Peptide-derivatives: Antimicrobial Agents with Potential Use in Nonspecific Immunity Modulation
Current Pharmaceutical Design Cocaine and HIV-1 Interplay in CNS: Cellular and Molecular Mechanisms
Current HIV Research CHF5074 Protects SH-SY5Y Human Neuronal-like Cells from Amyloidbeta 25-35 and Tumor Necrosis Factor Related Apoptosis Inducing Ligand Toxicity In Vitro
Current Alzheimer Research Food Addiction and Neuroimaging
Current Pharmaceutical Design